RCS - Issuer Direct NEWCO - Ad Scientiam Launches Study to Assess MSCopilot

Sanofi SAAnnouncement

12/09/2023 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230912:nRSL0552Ma&default-theme=true

RNS Number : 0552M  Issuer Direct Corp NEWCO  12 September 2023

Ad Scientiam Launches International Study to Assess Disability Progression in
Multiple Sclerosis With MSCopilot

PARIS, FRANCE / ACCESSWIRE / September 12, 2023 / Ad Scientiam, a global
leader in digital biomarkers, has announced a partnership with Sanofi to
launch MS-DETECT, an international, multicenter, longitudinal study. MS-DETECT
aims to evaluate the ability of MSCopilot®, a medical software device, to
detect early signs of disability worsening in people with multiple sclerosis
(PwMS). The study will draw upon Ad Scientiam's expertise in MS and is
financially supported by Sanofi.

Related Image
(https://cdn.newswire.com/files/x/45/c0/1fe4e6d4ef274dcc9b25ea7d2268.png)

AdS logo

Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central
nervous system that affects 2.8 million people worldwide. The disease is
characterized by early inflammatory demyelination and subsequent
neurodegeneration. Current clinical evaluation of PwMS relies mainly on the
Expanded Disability Status Scale (EDSS), which has several limitations. To
improve on these assessments, Ad Scientiam has developed MSCopilot®, a
software medical device that addresses four dimensions: ambulation/mobility,
upper extremity function, cognition, and low-contrast visual acuity.

MS-DETECT's main objective is to determine MSCopilot®'s ability to identify
subtle and early disability worsening. This will be performed by evaluating
MSCopilot® individual and/or composite scores as compared to the Multiple
Sclerosis Functional Composite (MSFC) and the EDSS.

"MS-DETECT is a pioneering large-scale longitudinal study that explores
digital biomarkers for the early detection of disease progression. This study
will provide important data to both clinicians and people living with
MS," according to Dr. Saad Zinaï, Chief Medical Officer at Ad Scientiam.

"Disability worsening in MS has been recently redefined and we now know that
this progression can occur independently of relapses. With MS-DETECT, we have
an opportunity to develop a digital solution to help detect and monitor the
effects of smoldering disease, and evolve treatment goals for MS
patients," explains Su-Peing Ng, Global Head of Medical Affairs - Specialty
Care at Sanofi.

The study also aims to assess the MSCopilot® performance, safety, usability
and satisfaction with the solution.

"Disease progression can be hard to detect in routine practice. I believe
these novel digital biomarkers are key to help clinicians make appropriate
treatment decisions and, ultimately, improve patients' care," said Prof.
Patrick Vermersch (Lille, France), Coordinating Investigator and Chairman of
the Study Steering Committee.

The MS-DETECT study will include 314 PwMS and will be conducted in the United
States, Canada, Germany, Italy, Spain, Denmark and France. Several
investigative sites have already been initiated in North America and Europe
and first patients are expected to participate in the study during Q3 2023.

Check our LinkedIn (https://pr.report/OQVqEA2v) , Facebook
(https://pr.report/SUT6y9rl) , Instagram  (https://pr.report/K5zM4gVF) pages
or visit adscientiam.com (https://pr.report/i8H5lpGc)

Contact Information

Saad Zinaï

Chief Medical Officer
szinai@adscientiam.com (mailto:szinai@adscientiam.com)

+33768008666

Matthieu Lamy

President
mlamy@adscientiam.com (mailto:mlamy@adscientiam.com)

+33768008666

SOURCE: Ad Scientiam

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABXGDCGSBDGXB